OncLive.com路 @OncLive 路 X路路 2 days agoScore70
Body
馃幆 62% confirmed ORR, 12.2-month median DOR, and 11.1-month median PFS with mocertatug rezetecan at the phase 3 dose in platinum-resistant ovarian cancer. Dana M. Chase, MD, of @UCLAHealthJCCC, on where B7-H4鈥搕argeted ADCs may fit 馃憞 #ESMO26 #gyncsm #ovca @myESMO https://hubs.li/Q04CjPYn0
81 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: OncLive.com 路 x.com